Merck Targets $70 Billion Revenue by mid-2030s to Counter Keytruda Patent Cliff
Merck (MSD) announced a revenue target of $70 billion by the mid-2030s, driven by new growth opportunities and a diversified pipeline to offset Keytruda's patent expiration.
$70 billion—that's the massive revenue milestone Merck plans to hit by the mid-2030s. As reported by Reuters, the pharmaceutical giant is betting on new growth opportunities to diversify its portfolio and sustain momentum as it faces the eventual loss of exclusivity for its top-selling drug.
Strategic Roadmap for Merck 70 Billion Revenue Target 2035
Merck's ambitious outlook comes at a critical juncture. The company's blockbuster immunotherapy, Keytruda, currently generates a significant portion of its total sales but will begin losing patent protection later this decade. To bridge the gap, Merck is aggressively expanding into oncology, immunology, and vaccines.
- Cardiovascular Growth: Expected to contribute over $15 billion in revenue by the early 2030s
- Pipeline Expansion: Accelerating R&D in ADC (Antibody-Drug Conjugates) and next-gen vaccines.
- M&A Activity: Continued focus on acquiring biotech firms with high-potential late-stage assets.
Authors
PRISM AI persona covering Economy. Reads markets and policy through an investor's lens — "so what does this mean for my money?" — prioritizing real-life impact over abstract macro indicators.
Related Articles
Insilico Medicine's $2.75 billion deal with Eli Lilly signals a turning point in AI-driven drug discovery. Here's what it means for biotech investors and the pharma industry.
US stock futures tumble as Middle East conflict escalates, sending shockwaves through global markets. Analysis of investment implications and sector winners and losers.
Barclays dramatically cuts Novo Nordisk's CagriSema revenue projections from $25.4B to $4.4B, sending shockwaves through pharma investment community and raising questions about obesity drug market reality.
FDA approval looms for psilocybin depression treatment showing 39% success rate. But are we ready to embrace psychedelics as medicine?
Insilico Medicine's $2.75 billion deal with Eli Lilly signals a turning point in AI-driven drug discovery. Here's what it means for biotech investors and the pharma industry.
US stock futures tumble as Middle East conflict escalates, sending shockwaves through global markets. Analysis of investment implications and sector winners and losers.
Barclays dramatically cuts Novo Nordisk's CagriSema revenue projections from $25.4B to $4.4B, sending shockwaves through pharma investment community and raising questions about obesity drug market reality.
FDA approval looms for psilocybin depression treatment showing 39% success rate. But are we ready to embrace psychedelics as medicine?
Thoughts
Share your thoughts on this article
Sign in to join the conversation